Fibrosis progression in chronic hepatitis C virus infection

Gut

Volumn 53, Issue 3, 2004, Pages 318-321

  McCaughan, G W ^a,b   George, J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVIRUS AGENT; INSULIN;

ALCOHOL CONSUMPTION; DISEASE COURSE; DISEASE DURATION; GENETIC POLYMORPHISM; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER TRANSPLANTATION; ONSET AGE; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEX; STEATOSIS;

DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; RISK FACTORS;

EID: 1242340457     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.026393     Document Type: Review

References (36)

1. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-56.
2. Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
3. Ryder SD. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-5.
4. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
5. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
6. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001;32:904-9.
7. Lagging LM, Westin J, Svensson E, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002;22:136-44.
8. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001;21:417-26.
9. Asselah T, Boyer N, Guimont M-C, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic heaptitis C. Gut 2003;52:1638-43.
10. Hui JM, Sud A, Farrell GC, et al. Chronic hepatitis C virus infection and insulin resistance: how do they interact, and what is the effect on hepatic fibrosis? Gastroenterology 2003;125:1695-1704.
11. Hui JM, Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002;17:873-81.
12. Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36:1266-72.
13. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
14. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci, 1997;42:2487-94.
15. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5.
16. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999;29:1743-51.
17. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44.
18. Paradis V, Dargere D, Vidaud M De, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999;30:968-76.
19. Marra F, Efsen E, Romanelli RG, et al. Liqands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-78.
20. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503.
21. Baroni GS, Pastorelli A, Manzin A, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999;19:212-19.
22. McCaughan GW, Gorrell MD, Bishop GA, et al. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev 2000;174:172-91.
23. Shackel NA, McGuinness PH, Abbott CA, et al. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002;160:641-54.
24. Heydtmann M, Shields P, McCaughan G, et al. Cytokines and chemokines in the immune response to hepatitis C infection. Curr Opin Infect Dis 2001;14:279-87.
25. Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996;24:759-65.
26. Nelson D, Soldevila-Pico C, Abdelmalek M, et al. Long-term use of recombinant interleukin 10 (IL-10) in patients with advanced chronic hepatitis C: insight into immunopathogenesis. Hepatology 2001;34(suppl):430A.
27. Powell EE, Edwards-Smith G, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-33.
28. Sonzogni L, Silvestri L, De Silvestri A, et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 2002;36:195-201.
29. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206-10.
30. Akuta N, Choyama K, Suzuki F, et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 allele. J Med Virol 2001;64:109-16.
31. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterohgy 2003; 124:352-60.
32. Muhlbauer M, Bosserhoff AK, Hartmann A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-93.
33. Ioannidis JP. Genetic associations: false or true? Trends Mol Med 2003;9:135-8.
34. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
35. Paizis G, Cooper ME, Schembri JM, et al. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 2002;123:1667-76.
36. Rimola A, Guevara G, Londono M, et al. Beneficial effect of antihyertensive drugs interfering with angiotensin on fibrosis associated with HCV infection recurrence after liver transplantation. Liver Transplant 2003;9:A132.